Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.58 |
| ▸ | ABL2 | P42684 | 6/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614822 | 1.00 | ABL1 (0.58) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL29614832 | 0.90 | FGFR4 (0.57) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL19307128 | 0.90 | FGFR4 (0.57) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL24449142 | 0.86 | ABL1 (0.55) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL19316724 | 0.86 | CDK8 (0.56) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL29614795 | 0.85 | CSF1R (0.61) | ABL1ABL2FGFR4SRCRET | |
| SCHEMBL19307123 | 0.85 | CSF1R (0.61) | ABL1ABL2FGFR4SRCRET | |
| SCHEMBL19322516 | 0.84 | SRC (0.58) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL19316725 | 0.82 | ABL1 (0.64) | ABL1ABL2FGFR4CDK1CDK2 | |
| SCHEMBL24448260 | 0.79 | ABL1 (0.73) | ABL1ABL2FGFR4CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885FGFR4 4217/4885 |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | ABL1 3590/4885ABL2 4545/4885FGFR4 4208/4885 |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885FGFR4 4217/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885ABL2 2755/4885FGFR4 4833/4885 |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | ABL1 3590/4885ABL2 4545/4885FGFR4 4208/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885FGFR4 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.